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Background: Soft-tissue sarcomas are rare malignant tumors of mesenchymal lineage that can arise in any part of
the body. Prognosis, and hence also treatment may vary according to histologic subtype and localization.
Angiogenesis is the process of forming new blood vessels from pre-existing ones. The deregulation of this process
is thought to be an important step in malignant transformation. This study investigates the prognostic impact of
platelet derived growth factor- (PDGF), vascular endothelial growth factor- (VEGF) and fibroblast growth factor (FGF)
families in soft-tissue sarcomas of the extremities & trunk (ET) and visceral & retroperitoneal (VR) locations.
Methods: Tumor samples from 181 patients (115 ET and 66 VR) with resected soft tissue sarcomas were collected
and tissue microarrays were constructed. Immunohistochemistry was used to evaluate angiogenic marker
expression. Recurrence-free survival (RFS), metastasis-free survival (MFS) and disease-specific survival (DSS) were used
as endpoints in prognostic impact assessment.
Results: In univariate analyses, almost all investigated angiogenic markers had prognostic impact in the ET group.
In contrast, only FGFR-1 showed any significant prognostic impact in the VR group. In the multivariate analyses,
PDGF-D (HR = 1.863, 95% CI = 1.057-3.283, P = 0.031), VEGFR-1 (HR = 2.106, 95% CI = 1.038-4.272, P = 0.039) and VEGF-A
(HR 2.095, 95% CI 1.028-4.271, P = 0.042) were independent negative prognosticators for DSS, MFS and RFS, respectively,
in the ET group. FGFR-1 was an independent positive prognosticator for DSS (HR = 0.243, 95% CI = 0.095-0.618, P = 0.003)
in the VR group.
Conclusions: Angiogenic molecules from the PDGF and VEGF families have prognostic impact in soft-tissue sarcomas
arising in the ET, but not in VR locations. In the latter histological grade and resection margins are the most important
prognostic factors.
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Soft tissue sarcomas (STS) constitute a highly heterogeneous
collection of tumors comprising over 50 histological
subtypes, arising from mesenchymal tissue and capable of
forming tumors in all parts of the human body [1]. This
group amounts to 0.5-1% of the annual tumor burden with
a mortality of about 40-60%, resulting in an estimated
11 280 cases and 3 900 deaths in the US in 2012 [2].* Correspondence: kilvaer@gmail.com
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stated.It is good practice to distinguish between STSs arising
in the extremity & trunk (ET), head & neck (HN) and
visceral & retroperitoneal (VR) localizations as treatment
and prognosis vary widely according to localization
[3]. Further subdivision, according to histological type,
malignancy grade, stage and vascular invasion among
others, can be conducted [3]. Definitive treatment is radical
surgery followed by radiotherapy in case of non-radical
surgical margins [4]. Adjuvant chemotherapy for adult STS
is still under investigation, and hence the routine use of
such treatment is today limited to the palliative setting [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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from pre-existing ones. Folkman and coworkers proved this
to be a pivotal step in carcinogenesis by showing that
tumors would not grow beyond > 2 mm in diameter
without forming vasculature [6,7]. In 2001, Hanahan and
Weinberg, suggested angiogenesis as one of the hallmarks
of cancer [8] and in the 2011 updated version angiogenesis
was still considered one of the most important aspects of
cancer progression [9].
Vascular endothelial growth factors (VEGF) and recep-
tors (VEGFR) are pivotal in endothelial cell proliferation
and sprouting during angio- and lymphangiogenesis [10].
Platelet-derived growth factors (PDGF) and receptors
(PDGFR) play an important part in the regulation of
tumor stroma through the recruitment of pericytes and
vascular smooth muscle cells helping to stabilize newly
formed vessels and through stimulation of stromal cells to
produce VEGF-A and thus drive angiogenesis [11,12].
Fibroblast growth factors (FGF) and receptors (FGFR)
drives endothelial cell proliferation and sprouting and
activate several molecules involved in extracellular matrix
remodelling including matrix metallo-proteinases and
urokinase-like plasminogen activator [13].
Our group has previously reported on the expression
of VEGF, PDGF and FGF families of growth factors in
STSs of all sites [14-16]. This report investigates the
differential impact of these growth factors in STSs
arising in ET versus VR localizations.
Methods
Patients and clinical samples
Primary tumor tissue from anonymized patients diagnosed
with STS at the University Hospital of North-Norway and
the Hospitals of Arkhangelsk County, Russia, from 1973
through 2006, were collected. In total 496 patients were
registered from the hospital databases. Of these, 388
patients were excluded from the study because of:
missing clinical data (n = 86), inadequate formalin-fixed
paraffin-embedded (FFPE) tissue blocks (n = 161), no
surgery performed and/or metastasis present at the
time of diagnosis (n = 55) or head and neck sarcomas
(n =13). Thus 115 patients with STSs of the extremities
and trunk wall and 66 patients with STSs of visceral or
retroperitoneal origin, with complete medical records and
FFPE tissue blocks were eligible.
This report includes follow-up data as of September
2009. The median follow-up was 53.9 (range 0.5-391.7)
months for extremity and trunk patients and 59.4
(range 0.10-366.7) months for visceral and retroperitoneal
patients. Complete demographic and clinical data
were collected retrospectively. Formalin-fixed and
paraffin-embedded tumor specimens were obtained from
the archives of the Departments of Pathology at the
University Hospital of North-Norway and the Hospitals ofArkhangelsk County, Russia. The tumors were graded
according to the French Fédération Nationale des centres
de Lutte Contre le Cancer (FNCLCC) system and histologi-
cally subtyped according to the World Health Organization
guidelines [1,17]. Wide resection margins were defined as
wide local resection with free microscopic margins or
amputation of the affected limb or organ.
Microarray construction
All sarcomas were histologically reviewed by two trained
pathologists (S. Sorbye and A. Valkov) and the most repre-
sentative areas of tumor cells (neoplastic mesenchymal cells)
were carefully selected and marked on the hematoxylin and
eosin (H/E) slide and sampled for the tissue microarray
(TMA) blocks. The TMAs were assembled using a
tissue-arraying instrument (Beecher Instruments, Silver
Springs, MD). The Detailed methodology has been
previously reported [18]. Briefly, we used a 0.6 mm
diameter stylet, and the study specimens were routinely
sampled with four replicate core samples from different
areas of neoplastic tissue. Normal tissue from the patients
was used as staining control.
To include all core samples, 12 TMA blocks were
constructed. Multiple 5-μm sections were cut with a
Micron microtome (HM355S) and stained by specific
antibodies for immunohistochemistry (IHC) analysis.
Immunohistochemistry
The applied antibodies were subjected to in-house
validation by the manufacturer for IHC analysis on
paraffin-embedded material. The detailed methodology
has previously been reported [14-16].
Scoring of immunohistochemistry
The ARIOL imaging system (Genetix, San Jose, CA)
was used to scan the slides of antibody staining of
the TMAs and the dominant staining intensity was scored
as: 0 = negative; 1 = weak; 2 = intermediate; 3 = strong
semi-qantitively on computer screen. The detailed
methodology has previously been reported and cut-off
values chosen were the same as in our previous studies
[14-16]. High expression in tumor cells were defined as ≥ 1
(VEGF-C), ≥ 1.5 (PDGF-A, PDGF-C, PDGF-B, VEGF-A,
VEGF-D, VEGFR-1-2 and -3) and ≥ 2 (PDGF-D, PDGFR-α,
PDGFR-β, FGF2 and FGFR-1).
Statistical methods
All statistical analyses were done using the statistical
package SPSS (Chicago, IL), version 16. The IHC scores
from each observer were compared for interobserver
reliability by use of a two-way random effect model with
absolute agreement definition. The intraclass correlation
coefficient (reliability coefficient) was obtained from these
results. The Chi-square test and Fishers Exact test were
Table 1 Prognostic clinicopathological variables as predictors for disease-specific survival, metastasis and local recurrence in patients with resected Extremitiy
& Trunk and Visceral & Retroperitoneal soft-tissue sarcomas (univariate analyses, log rank test, n = 115 and 66 respectively)



























≤ 20 years 12 42 0.431 42 0.129 73 0.690 1 0 <0.001 100 0.112 100 0.786
21-60 years 48 61 63 69 36 71 67 71
> 60 years 55 55 69 64 29 43 44 62
Gender
Male 57 56 0.298 66 0.368 66 0.759 15 79 0.039 86 0.022 66 0.799
Female 58 54 61 67 51 51 48 68
Patient nationality
Norwegian 67 65 0.004 74 0.008 71 0.249 54 62 0.051 59 0.122 66 0.892
Russian 48 42 48 57 12 36 46 59
Histological entity
Pleomorphic sarcoma 48 42 0.004 61 0.001 56 0.664 6 50 0.917 67 0.264 40 0.274
Leiomyosarcoma 9 100 78 78 39 55 46 77
Liposarcoma 18 83 94 89 13 62 81 54
Fibrosarcoma 12 57 67 55 0
Angiosarcoma 5 40 20 67 2 50 50 50
Rhabdomyosarcoma 5 60 60 60 1 100 100
MPNST 5 53 60 60 4 67 100 100
Synovial sarcoma 10 13 30 64 1 100 0 0
Sarcoma NOS 3 100 67 67 0
Tumor size
< 5 cm 38 70 0.048 81 0.053 74 0.085 11 82 0.107 73 0.259 89 0.006
5-10 cm 45 48 53 61 24 62 62 70


















Table 1 Prognostic clinicopathological variables as predictors for disease-specific survival, metastasis and local recurrence in patients with resected Extremitiy
& Trunk and Visceral & Retroperitoneal soft-tissue sarcomas (univariate analyses, log rank test, n = 115 and 66 respectively) (Continued)
Malignancy grade
1 29 89 <0.001 89 0.001 85 0.054 23 78 0.005 77 0.051 86 0.046
2 41 56 65 60 29 46 42 58
3 45 35 43 57 14 46 47 49
Vascular invasion
Absent 64 70 <0.001 85 <0.001 79 <0.001 43 59 0.656 60 0.847 66 0.675
Present 50 35 33 43 20 51 54 78
Missing 1 3
Tumor depth
Superficial 12 91 0.010 100 0.012 91 0.041 32
Deep 103 51 59 63 34
Resection margins
Wide 61 66 0.004 72 0.045 82 <0.001 50 65 0.021 59 0.654 90 <0.001
Non-wide 54 44 54 46 16 50 53 44

















Table 2 Angiogenic markers as predictors for disease-specific survival, metastasis and local recurrence in patients with
resected soft-tissue sarcomas of the extremities or trunk (univariate analyses, log rank test, n = 115)
Disase-specific survival Metastasis-free survival Recurrence-free survival
Marker expression Patients (n) 5-Year survival (%) P 5-Year survival (%) P 5-Year survival (%) P
PDGF-A
Low 54 60 0.035 74 0.007 79 0.012
High 58 52 51 55
Missing 3
PDGF-B
Low 44 68 0.006 78 0.003 82 0.015
High 68 48 52 56
Missing 3
PDGF-C
Low 31 71 0.032 68 0.214 68 0.564
High 80 50 61 65
Missing 4
PDGF-D
Low 73 67 0.003 70 0.051 77 0.002
High 40 34 49 42
Missing 2
PDGFR-α
Low 69 67 0.002 74 0.002 77 0.011
High 43 38 42 45
Missing 3
PDGFR-β
Low 85 64 0.029 72 0.002 69 0.825
High 24 32 35 58
Missing 6
VEGF-A
Low 60 65 0.001 75 0.001 77 0.002
High 51 43 48 51
Missing 4
VEGF-C
Low 69 55 0.476 68 0.083 68 0.232
High 38 60 56 63
Missing 8
VEGF-D
Low 84 57 0.131 67 0.081 70 0.177
High 29 50 51 55
Missing 2
VEGFR-1
Low 67 63 0.002 77 <0.001 72 0.036
High 44 46 43 58
Missing 4
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Table 2 Angiogenic markers as predictors for disease-specific survival, metastasis and local recurrence in patients with
resected soft-tissue sarcomas of the extremities or trunk (univariate analyses, log rank test, n = 115) (Continued)
VEGFR-2
Low 78 58 0.332 67 0.189 71 0.240
High 28 52 53 57
Missing 9
VEGFR-3
Low 75 60 0.053 70 0.008 70 0.159
High 34 45 46 57
Missing 6
FGF2
Low 75 61 0.033 66 0.214 70 0.648
High 35 49 56 67
Missing 6
FGFR-1
Low 83 58 0.460 64 0.411 66 0.768
High 26 47 55 71
Missing 6
Abbreviations: PDGF Platelet-derived growth factor, PDGFR Platelet-derived growth factor receptor, VEGF Vascular endothelial growth factor, VEGFR Vascular
endothelial growth factor receptor, FGF Fibroblast growth factor, FGFR Fibroblast growth factor receptor.
Kilvaer et al. BMC Clinical Pathology 2014, 14:5 Page 6 of 11
http://www.biomedcentral.com/1472-6890/14/5used to examine the association between molecular marker
expression and various clinicopathological parameters.
Univariate analyses were done using the Kaplan-Meier
method, and statistical significance between survival curves
was assessed by the log-rank test. Disease-specific survival
(DSS) was determined from the date of diagnosis to the
time of cancer related death. Metastasis-free survival (MFS)
was defined from the date of diagnosis to the clinical
appearance of the first metastasis. Recurrence-free survival
(RFS), was defined from the date of diagnosis to the clinical
appearance of the first recurrence. To assess the independ-
ent value of different pretreatment variables on survival,
metastasis and local recurrence, in the presence of other
variables, multivariate analyses were carried out using
the Cox proportional hazards model. Only variables of
significant value from the univariate analyses were
entered into the Cox regression analysis. Probability
for stepwise entry and removal was set at .05 and .10,
respectively. The significance level used for all statistical
tests was P < 0.05.
Ethical clearance
The Norwegian National Data Inspection Board and
The Regional Committee for Research Ethics (Northern
Norway) approved the study.
Results
Clinicopathological variables
The clinicopathological variables are summarized in
Table 1. In the ET group, comprising 115 patients, medianage was 59 (range 0-89) years, 50% of the patients were
male, 67 patients were Norwegian and 48 Russian and
68% of the tumors were located in the extremities. Of the
histological subtypes represented, 48 were undifferentiated
pleomorphic sarcomas, 18 liposarcomas, 12 fibrosarcomas,
10 synovial sarcomas, 9 leiomyosarcomas, 5 angiosarcomas,
5 rhabdomyosarcomas, 5 malignant peripheral nerve
sheath tumors (MPNST) and 3 sarcoma not otherwise
specified (NOS).
In the VR group, median age was 58 (range 13-88) years,
23% of the patients were male and 54 patients were
Norwegian and 12 Russian. Of the histological subtypes
represented, 39 were leiomyosarcomas, 13 liposarco-
mas, 6 pleomorphic sarcomas, 4 neurofibrosarcomas/
MPNSTs, 2 angiosarcomas, 1 rhabdomyosarcoma and
1 synovial sarcoma.
Interobserver variability
Interobserver scoring agreement was tested for PDGF-B,
PDGFR-α, VEGF-C, VEGFR-3, FGF2 and FGFR1 and found
to be good (0.77-0.90, P < 0.001) [14-16].
Univariate analyses
The impact of the clinicopathological variables on DSS,
MFS and RFS in the ET group are summarized in
Table 1. Patient nationality (P = 0.004), histological entity
(p = 0.004), tumor size (p = 0.048), malignancy grade
(P < 0.001), vascular invasion (P <0.001), tumor depth
(P = 0.010) and resection margins (P = 0.004) were all
prognostic indicators of DSS. Patient nationality (P = 0.008),
Table 3 Angiogenic markers as predictors for disease-specific survival, metastasis and local recurrence in patients with
resected visceral & retroperitoneal soft-tissue sarcomas (univariate analyses, log rank test, n = 66)
Disase-specific survival Metastasis-free survival Recurrence-free survival
Marker expression Patients (n) 5-Year survival (%) P 5-Year survival (%) P 5-Year survival (%) P
PDGF-A
Low 23 49 0.473 63 0.593 65 0.315
High 39 63 54 73
Missing 4
PDGF-B
Low 14 54 0.604 82 0.088 61 0.291
High 48 59 51 73
Missing 4
PDGF-C
Low 20 39 0.297 59 0.986 53 0.045
High 41 65 56 76
Missing 5
PDGF-D
Low 48 52 0.078 52 0.197 70 0.343
High 15 80 73 59
Missing 3
PDGFR-α
Low 41 56 0.672 61 0.527 71 0.761
High 21 61 51 66
Missing 4
PDGFR-β
Low 58 57 0.360 54 0.532 70 0.766
High 4 75 75 75
Missing 4
VEGF-A
Low 34 51 0.326 64 0.719 64 0.054
High 29 68 53 79
Missing 3
VEGF-C
Low 34 66 0.402 69 0.071 62 0.051
High 29 50 45 84
Missing 3
VEGF-D
Low 34 60 0.856 62 0.388 63 0.116
High 30 55 51 78
Missing 2
VEGFR-1
Low 37 55 0.724 63 0.358 70 0.510
High 25 63 49 71
Missing 3
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Table 3 Angiogenic markers as predictors for disease-specific survival, metastasis and local recurrence in patients with
resected visceral & retroperitoneal soft-tissue sarcomas (univariate analyses, log rank test, n = 66) (Continued)
VEGFR-2
Low 44 55 0.858 63 0.446 69 0.821
High 19 67 48 75
Missing 3
VEGFR-3
Low 36 54 0.552 59 0.821 65 0.220
High 25 61 52 76
Missing 5
FGF2
Low 39 56 0.805 51 0.214 74 0.748
High 20 65 67 66
Missing 7
FGFR-1
Low 43 45 0.023 56 0.385 68 0.448
High 20 89 63 78
Missing 3
Abbreviations: PDGF Platelet-derived growth factor, PDGFR Platelet-derived growth factor receptor, VEGF Vascular endothelial growth factor, VEGFR Vascular
endothelial growth factor receptor, FGF Fibroblast growth factor, FGFR Fibroblast growth factor receptor.
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vascular invasion (P < 0.001), tumor depth (P = 0.012)
and resection margins (P = 0.045) were prognostic indicators
of MFS. Finally, vascular invasion (P < 0.001), tumor
depth (P = 0.041) and resection margins (P < 0.001) were
prognostic indicators of RFS.
The impact of the angiogenic markers on DSS,
MFS and RFS in the ET group are summarized in
Table 2. PDGF-A (P = 0.035), PDGF-B (P = 0.006),
PDGF-C (P = 0.032), PDGF-D (P = 0.003), PDGFR-α
(P = 0.002), PDGFR-β (P = 0.029), VEGF-A (P = 0.001),
VEGFR-1 (P = 0.001) and FGF2 (P = 0.033) were prognostic
indicators of DSS. PDGF-A (P = 0.007), PDGF-B (P = 0.003),
PDGFR-α (P = 0.002), PDGFR-β (P = 0.002), VEGF-A
(P = 0.001), VEGFR-1 (P < 0.001) and VEGFR-3 (P = 0.008)
were prognostic indicators of MFS. PDGF-A (P = 0.012),
PDGF-B (P = 0.015), PDGFR-α (P = 0.011), VEGF-A
(P = 0.002) and VEGFR-1 (P = 0.036) were prognostic
indicators of RFS.
The impact of the clinicopathological variables on
DSS, MFS and RFS in the VR group are summarized
in Table 1. Age (P < 0.001), gender (P = 0.039), malig-
nancy grade (P = 0.005) and resection margins (P = 0.021)
were prognostic indicators of DSS. Gender (P = 0.022)
was a prognostic indicator of MFS and tumor size
(P = 0.006), malignancy grade (P = 0.046) and resec-
tion margins (P < 0.001) were prognostic indicators
of RFS.
The impact of angiogenic markers on DSS, MFS
and RFS in the VR group is summarized in Table 3.FGRF-1 (P = 0.023) was the only prognostic indicator
for DSS and PDGF-C (P = 0.045) for RFS.
Multivariate cox proportional hazards analysis
Table 4 presents multivariate analyses of clinicopathologi-
cal and angiogenic marker variables with respect to DSS,
MFS and RFS in the ET and VR groups, respectively.
In the ET group, high malignancy grade (P < 0.001),
the presence of vascular invasion (P = 0.011), non-wide
resection margins (P = 0.039) and high expression of
PDGF-D (HR = 1.863, 95% CI = 1.057-3.283, P = 0.031)
were significant independent prognostic indicators of
DSS. Further, the presence of vascular invasion (P < 0.001)
and high expression of VEGFR-1 (HR = 2.106, 95%
CI = 1.038-4.272, P = 0.039) were significant independ-
ent prognostic factors of MFS, while the presence of
vascular invasion (P = 0.045), non-wide resection margins
(P = 0.008) and high expression of VEGF-A (HR 2.095, 95%
CI 1.028-4.271, P = 0.042) were significant independent
prognostic factors of RFS.
In the VR group, high malignancy grade (P = 0.003)
and non-wide resection margins (P = 0.014) were sig-
nificant independent adverse prognostic indicators of
DSS whereas high FGFR-1 expression (HR = 0.243,
95% CI = 0.095-0.618, P = 0.003) was an independent
positive prognostic indicator of DSS. Female gender
(P = 0.038) was an independent negative prognostic
indicator of MFS while non-wide resection margins
(P < 0.001) was an independent negative prognostic
indicator of RFS.
Table 4 Multivariate analyses of clinopathological variables and angiogenic markers as prognostic values for disease-specific
survival, metastasis and local recurrence in patients with resected soft-tissue sarcomas of the trunk or extremities
(cox proportional hazards test)
Disase-specific survival Metastasis-free survival Recurrence-free survival




2 4.066 1.389-11.901 0.010
3 6.025 2.058-17.634 0.001
Vascular invasion
Absent 1.000 1.000 1.000
Present 2.141 1.188-3.859 0.011 5.284 2.418-11.544 <0.001 2.135 1.019-4.475 0.045
Resection margins
Wide 1.000 1.000
Non-wide 1.818 1.032-3.203 0.039 2.687 1.289-5.602 0.008
PDGF-B
Low 1.000
High 2.099 0.937-4.706 0.072
PDGF-D
Low 1.000 1.000
High 1.863 1.057-3.283 0.031 1.844 0.931-3.653 0.079
VEGF-A
Low 1.000
High 2.095 1.028-4.271 0.042
VEGFR-1
Low 1.000




Female 4.612 1.089-19.536 0.038
Malignancy grade
1 1.000 0.003* 1.000 0.061
2 4.812 1.823-12.705 0.002 2.069 0.630-6.794 0.231
3 5.646 1.790-17.804 0.003 5.665 1.330-24.123 0.019
Resection margins
Wide 1.000 1.000
Non-wide 2.712 1.222-6.018 0.014 11.996 3.128-46.005 <0.001
PDGF-C
Low 1.000
High 0.413 0.157-1.089 0.074
FGFR-1
Low 1.000
High 0.243 0.095-0.618 0.003
Abbreviations: HR Hazard ratio, CI Confidence interval, VEGF Vascular endothelial growth factor, VEGFR Vascular endothelial growth factor receptor, PDGFR Platelet-derived
growth factor receptor, FGFR Fibroblast growth factor receptor, *overall significance as prognostic factor.
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In our univariate analyses high expression of most examined
angiogenic markers were prognosticators of DSS and/or
MFS and/or RFS in the ET group. Further, PDGF-D
was an independent negative prognostic indicator of DSS,
VEGFR-1 an independent negative prognostic indicator
of MFS and VEGF-A an independent negative prognostic
indicator of RFS. In contrast, only FGFR-1 was a prognosti-
cator of DSS in both the univariate and multivariate
analyses of the VR group. To our knowledge, this is
the first comparison of the expression of angiogenic
molecules in ET versus VR STSs.
Current knowledge of the importance of tumor
localization (ET versusVR tumors) when it comes to the
prognostic impact of angiogenic markers in STSs is
limited. Yudoh et. al. investigated the level of VEGF-A in
tissue from ET patients and found high levels to predict
survival, local recurrence and metastasis [18]. We have
previously reported on the expression of PDGFs, VEGFs
and FGFs in a larger cohort of STS of mixed sites
and histology and found high expression of VEGFR-3,
PDGF-B and FGF2 to have independent negative
prognostic impact on DSS [14-16]. When comparing
the expression of angiogenic markers based on tumor
location, it becomes apparent that these variables almost
exclusively have prognostic impact in STS arising in the
ET group (Tables 2, 3 and 4). This difference could to
some extent be due to a smaller number of patients in the
VR group, with a resulting increased risk of false negative
results. However, near all angiogenic markers showed
significant prognostic impact in the univariate analyses of
the ET group, whereas only FGFR-1 showed prognostic
impact in the VR group. Table 1 summarizes the clino-
pathological values in the ET and VR groups and it is
apparent that the VR group contains a higher percentage of
leiomysarcomas and liposarcomas. The different distribu-
tion of histologies between the ET and VR groups might
suggest that angiogenic markers have higher impact in
STSs arising in ET locations. Another explanation may be
that ET tumors, even the slow growing ones, will produce
symptoms when they reach a certain size due to limits cre-
ated by connective and muscle tissue and blood and lymph
vessels. VR tumors could in contrast grow to significant size
before producing symptoms. This may explain our results
as VR tumors in many cases only are found after the angio-
genic switch have occurred, thus the impact of angiogenic
markers have been negated in these tumors.
In the PDGF-axis, all markers were prognosticators of
DSS, all but PDGF-C were prognosticators of MFS and
all but PDGF-C and PDGFR-β were prognosticators of
RFS in the ET group (Table 2), while none of the PDGFs
were prognosticators in the VR group. Further, PDGF-D
was found to be an independent negative prognostic
factor for DSS in the ET group. In our previous study,PDGF-B was an independent prognosticator of DSS [15],
and in this study PDGF-D is an independent prognosticator
of DSS. PDGF-B binds all PDGFRs while PDGF-D binds
PDGFR-αβ and-ββ [11]. Both PDGF-B and PDGF-D has
been shown to exhibit similar and extensive angiogenic
and transforming abilities [19,20]. Although our results
cannot distinguish whether PDGF signalling drives tumor
development through angiogenesis or other pathways,
they strongly suggest PDGF signalling to be an important
part of STS growth and progression.
In the VEGF-axis, VEGF-A, and VEGFR-1 were
prognosticators of DSS, MFS and RFS in the ET group,
while none of the VEGFs were prognosticators in the VR
group (Table 2). Further, VEGFR-1 was an independent
prognostic indicator of MFS and VEGF-A was an inde-
pendent prognostic indicator of RFS in the ET group.
VEGF-A signalling is the major angiogenic pathway,
and high tumor expression and availability in serum
has previously been associated with malignancy grade,
metastasis, local recurrence and worse overall survival in
STS patients [18,21-26]. VEGFR-1 is thought to modulate
VEGF-A signalling through VEGFR-2, has anti-angiogenic
properties in its soluble form, and has been linked to
metastasis in experimental studies suggesting a feasible
biological link for our finding in these STS patients
[27,28]. This latter finding is quite interesting as anti-
bodies and small-molecules targeting VEGFR-1 are being
developed [29,30].
In the FGF-axis, FGF-2 was an unfavorable prognostic
indicator of DSS in ET group. FGF2 is thought to drive cell-
cycling, activate extracellular matrix remodelling and to
rescue PDGF-B and VEGF-A driven angiogenesis in the
presence of their respective inhibitors [13,31,32]. Surpris-
ingly, FGFR-1 was an independent positive indicator of DSS
in the VR group. To our knowledge these are new data, but
these results have to be validated before a firm conclusion
may be drawn due to the low number of patients.
This study enhances our current knowledge on angiogenic
prognosticators in STSs, strongly indicates the involvement
of the PDGF and VEGF pathways in ET STS development
and adds to the growing body of evidence suggesting
that STSs of different sites and histology should be analyzed
independently in future studies. Further emphasis should
also be put on validating VEGFR-1 as a predictor of
MFS in ET STS patients, as these patients may benefit
from adjuvant therapy targeting VEGFR-1.
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